Literature DB >> 6843933

Intraamniotic injection of ethacridine for second-trimester induction of labor.

K H Tien.   

Abstract

In the People's Republic of China one of the most widely used methods of second-trimester abortion is the intraamniotic injection of ethacridine (Rivanol). Intraamniotic ethacridine produces fetal death, a fall in maternal urinary estriol excretion, and a rise in prostaglandin levels. Although the induction time is longer than that usually seen with prostaglandins, the method is not ordinarily associated with vomiting, cervical injury, or the delivery of a live fetus. In a series of 10,302 cases, the success rate was 96.4% and the incidence of associated complications was low.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6843933

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

1.  Induction of second trimester abortion by intraamniotic instillation of Rivanol (ethacridine) combined with oxytocin infusion.

Authors:  S Gardó; M Nagy
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

2.  Effectiveness and safety of double-balloon catheter versus intra-amniotic injection of ethacridine lactate for termination of second trimester pregnancy in patients with liver dysfunction.

Authors:  Na Li; Peng Wu; Jie Zhao; Ling Feng; Fu-Yuan Qiao; Wan-Jiang Zeng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-02-12

3.  Lack of coagulation defects after the intraamniotic instillation of ethacridine (Rivanol) for second trimester abortion.

Authors:  F K Beller; R E Zimmermann; U H Winkler; D Seitzer; W Holzgreve
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

4.  Prophylactic uterine artery embolization in second-trimester pregnancy termination with complete placenta previa.

Authors:  Yinfeng Wang; Changchang Hu; Ningpin Pan; Chaolu Chen; Ruijin Wu
Journal:  J Int Med Res       Date:  2018-10-14       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.